EAU2023 has come to an end. Scientific sessions demonstrated the constant and solid progress EchoLaser is making as a game changer for the treatment of BPH:

• The first randomized clinical trial vs TURP shows that 96% of the patients treated with EchoLaser were able to preserve ejaculation.
• The first comparative analysis EchoLaser vs Rezum (Boston Scientific) shows that not going through the urethra makes a significant impact on patients suffering from Benign Prostatic Hyperplasia who seek the optimal treatment.
• Although there are many treatment options for patients suffering from Benign Prostatic Hyperplasia, none has proven to be optimal so far and bears risks for patients. Such risks are minimized by EchoLaser.Which was proven to be safe, efficacious and results are stable over time (3 years).

Patients suffering from Benign Prostatic Hyperplasia have now a new treatment modality to discuss with their urologist: EchoLaser, CE marked and FDA cleared